Abstract:Abstract Background Biologics nurses play a critical role in the management of patients receiving treatment for Inflammatory Bowel Disease (IBD).Their impact spans various facets of patient care and service management. Prior to December 2021 all patients who required biological therapy were reviewed by any member of the IBD nursing team. This review would entail a comprehensive history taken, screening bloods ordered and explained and a thorough ex[planation of the risks and benefits of the medication including a detailed explanation of the use of the drug. The nurses were also responsible for the preparation of biologic prescriptions and checking of bloods. With a number of nurses undertaking this can lead to duplication of work or patients not receiving medication timely. Methods A business was written to secure funding for extra nurses and was unsuccessful. At the time of the Covid pandemic workload escalated to an extent that the current IBD Helpline and nurse led clinics could not continue in their present form. Resulting in a suspension of nurse clinics which led to a backlog of reviewing patients who required biological therapy, thus delaying their treatment. A meeting was convened with the senior management team and staffing numbers were increased resulting in the development of a biologics nurse. Results A band 6 biologics nurse was employed who completely transformed the biologics service. One person completing a role independently assumes total responsibility for all of the tasks annexed to the role. This involved patients education and support, monitoring and assessment of patients, coordination and communication with patients and relevant departments. It also included quality improvement, patient advocacy, emotional support to patients and patient empowerment/ One person responsible for this role has now led to a reduction in complaints, more timely treatment, less missed treatment appointments and a single point of contact for patients and departments. Our biologics nurse has not only achieved all of these roles but has been fundamental in the biologic switch to more coast effective biological therapies. Conclusion The impact of a dedicated biologics nurse in an IBD service is significant. They enhance the overall quality of care, improve patient outcomes, and contribute to the efficient functioning of the service by ensuring proper management, patient education, and support throughout the treatment journey. The team have had an increased number of praise and favourable comments from patients, families and departments that interact with our service such as the Medical Day Unit. The introduction of this role has been invaluable to our service has increased to such an amount that the team could do with a second nurse in post.

Equity, expense, and expertise in biologic commissioning: adding the patient to the equation

Biological Therapies in Immune-Mediated Inflammatory Diseases: Can Biosimilars Reduce Access Inequities?

Approaches to optimising access to NICE-approved biologic anti-TNFs for patients with rheumatoid arthritis with moderately active disease

P889 Facilitating equitable IBD care trust-wide: a need for treatment targets in IBD?

Pharmacoequity & Biologics In The Allergy Clinic: Providing The Right Care, At The Right Time, Every time, To Everyone

Optimizing severe asthma care by consulting an asthma expertise team for biologics

N39 Exploring the impact of an Inflammatory Bowel Disease Biologics Nurse on the management of a biologics service

P031 Experience from a UK dermatology regional virtual biologics and high-cost drugs multidisciplinary team

Optimizing Selection of Biologics in Inflammatory Bowel Disease: Development of an Online Patient Decision Aid Using Conjoint Analysis

Transitioning patients from intravenous to subcutaneous infliximab and vedolizumab for inflammatory bowel disease: what is the opportunity cost of improving access to healthcare?

Overcoming barriers to biosimilar adoption: real-world perspectives from a national payer and provider initiative

Severe asthma biologics use in England: a need to increase use and reduce inequity

P1038 Does combination immunomodulator therapy impact real-world biologic effectiveness in Inflammatory Bowel Diseases?A propensity score analysis in patients treated with anti-TNF and non-anti-TNF biologics in the UK IBD BioResource

Biosimilars and access to biologic therapy in immune-mediated diseases

Patient's and Consultant's Views and Perceptions on Switching from an Originator Biologic to Biosimilar Medication: A Qualitative Study

Patient access to biological medications for ulcerative colitis

Navigating the landscape of SLE treatment: An expert viewpoint on the rationality and limitations of early biologic intervention

Mixed-methods evaluation of an enhanced asthma biologics clinical pathway in the West Midlands UK

Under the Umbrella of Clinical Pharmacology: Inflammatory Bowel Disease, Infliximab and Adalimumab, and a Bridge to an Era of Biosimilars

Patient preferences in chronic immune-mediated inflammatory diseases potentially treated with biological drugs: discrete choice analysis using real-world data analysis

Cost-Effectiveness of Biologic Therapies for the Treatment of Moderate to Severe Psoriasis in the United Kingdom